drugset
drugset / Trial / NCT03141983

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983 ↗

Phase 2 Completed 80 enrolled University of Pennsylvania National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION) is a phase II multi-center study to evaluate the safety and tolerability of anakinra, an IL-1 receptor antagonist, for patients treated with maintenance hemodialysis.

Timeline

Start
2017-12-15
Primary completion
2021-09-02
Completion
2021-09-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic 100 mg Intravenous

Indications

end stage renal failure